These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20946669)

  • 1. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Manolakis AC; Kapsoritakis AN; Georgoulias P; Tzavara C; Valotassiou V; Kapsoritaki A; Potamianos SP
    BMC Gastroenterol; 2010 Oct; 10():118. PubMed ID: 20946669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease.
    Foell D; Kucharzik T; Kraft M; Vogl T; Sorg C; Domschke W; Roth J
    Gut; 2003 Jun; 52(6):847-53. PubMed ID: 12740341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity.
    Oikonomou KA; Kapsoritakis AN; Theodoridou C; Karangelis D; Germenis A; Stefanidis I; Potamianos SP
    J Gastroenterol; 2012 May; 47(5):519-30. PubMed ID: 22200942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
    Huong BT; Hien NM; Dung NT; Quang DM; Vinh NT; Tu TT; Chi TK; Phuong LB; Nhan NT
    Med Arch; 2024; 78(2):105-111. PubMed ID: 38566874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
    Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
    PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases.
    Heydari R; Fayazzadeh S; Shahrokh S; Shekari F; Farsad F; Meyfour A
    Inflamm Bowel Dis; 2024 May; 30(5):795-807. PubMed ID: 37855715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
    Schoepfer AM; Trummler M; Seeholzer P; Seibold-Schmid B; Seibold F
    Inflamm Bowel Dis; 2008 Jan; 14(1):32-9. PubMed ID: 17924558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA; Leach ST; Day AS
    Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
    Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
    J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease.
    Manolakis AC; Christodoulidis G; Kapsoritakis AN; Georgoulias P; Tiaka EK; Oikonomou K; Valotassiou VJ; Potamianos SP
    World J Gastroenterol; 2017 Jan; 23(3):437-446. PubMed ID: 28210079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The central role of psychopathology and its association with disease severity in inflammatory bowel disease and irritable bowel syndrome.
    Piacentino D; Cesarini M; Badiali D; Pallotta N; Biondi M; Corazziari ES
    Riv Psichiatr; 2019; 54(2):75-83. PubMed ID: 30985832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease.
    Kapsoritakis AN; Kapsoritaki AI; Davidi IP; Lotis VD; Manolakis AC; Mylonis PI; Theodoridou AT; Germenis AE; Potamianos SP
    BMC Gastroenterol; 2008 Nov; 8():55. PubMed ID: 19036126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.
    Morales W; Rezaie A; Barlow G; Pimentel M
    Dig Dis Sci; 2019 Nov; 64(11):3115-3121. PubMed ID: 31152332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Emotional and personality features of patients with irritable bowel syndrome and bowel inflammatory diseases].
    Mnatsakanyan MG; Dyukova GM; Pogromov AP; Tashchyan OV
    Klin Med (Mosk); 2016; 94(10):764-9. PubMed ID: 30299020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.